What do systematic reviews say?

Azoles vs moderate‐potent corticosteroid/azole combinations

Azoles showed no clear difference in mycological cure Negative KOH microscopy and culture. Treatment… compared with moderate‐potent corticosteroid/azole combinations (low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.99 [0.93, 1.05]
  6 studies · 625 participants
  Low

Azoles vs moderate‐potent corticosteroid/azole combinations

It is very uncertain whether azoles changes clinical cure (immediately at end of treatment) Resolution of… compared with moderate‐potent corticosteroid/azole combinations (very low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 0.67 [0.53, 0.84]
  4 studies · 353 participants
  Very low

Azoles vs moderate‐potent corticosteroid/azole combinations

It is very uncertain whether azoles changes adverse effects Reported by investigators 'and' or 'or' participants compared with moderate‐potent corticosteroid/azole combinations (very low certainty).

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  RR 1.36 [0.68, 2.69]
  5 studies · 668 participants
  Very low

Azoles vs moderate‐potent corticosteroid/azole combinations

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Azoles vs moderate‐potent corticosteroid/azole combinations

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 1 participants
  Low

Azoles vs moderate‐potent corticosteroid/azole combinations

• Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Inspection vs no intervention

Inspection showed no clear difference in fatal and non‐fatal injuries in RCT, short‐term compared with no intervention (low certainty).

• Occupational safety and health enforcement tools for preventing occupational diseases and injuries 2013 · Cochrane Headline outcomes only
  RR 1.04 [0.9, 1.21]
  Studies not reported
  Low

Inspection vs no intervention

Inspection showed no clear difference in fatal and non‐fatal injuries in CBA, medium‐term compared with no intervention (low certainty).

• Occupational safety and health enforcement tools for preventing occupational diseases and injuries 2013 · Cochrane Headline outcomes only
  RR 0.87 [0.75, 1.02]
  Studies not reported
  Low
• Occupational safety and health enforcement tools for preventing occupational diseases and injuries 2013 · Cochrane Headline outcomes only
  RR 0.77 [0.64, 0.92]
  Studies not reported
  Low

Inspection vs no intervention

• Occupational safety and health enforcement tools for preventing occupational diseases and injuries 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Inspection vs no intervention

• Occupational safety and health enforcement tools for preventing occupational diseases and injuries 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  High